NCT04785820 was a phase II study to evaluate the safety and efficacy of RO7247669 (a PD-1-LAG-3 antibody) and RO7121661 (a PD-1-TIM-3 antibody), compared to nivolumab, in patients diagnosed with advanced or metastatic ESCC. Here, PDCD1 is linked to esophageal squamous cell carcinoma.